Lumos Diagnostics has today announced that it has entered into a partnering agreement with US-based market access consultancy, PRO-spectus, to support the marketing, market access and reimbursement of its flagship point-of-care test, FebriDx®.
PRO-spectus is a leading independent provider of patient access programs and specialty pharmacy services for the life sciences industry.
Under the agreement, PRO-spectus will provide a comprehensive suite of strategic and operational services designed to help accelerate patient access to FebriDx® by supporting healthcare providers in securing appropriate reimbursement.
These will include:
Development of strategic collateral to communicate FebriDx’s® clinical and economic value across multiple healthcare settings.
- A dedicated helpline to respond to coding, coverage, and payment inquiries from both internal stakeholders and external customers.
- A field support team with expertise in provider adoption of new technologies, working directly with strategic accounts to deliver reimbursement education, navigate payor requirements, and resolve site-specific billing and coding challenges.
Lumos CEO, Doug Ward, said:
“This partnership with PRO-spectus is an important step in accelerating the commercial adoption of FebriDx® in the US market. By combining our clinically proven diagnostic technology with PRO-spectus’ market access expertise, we can better equip healthcare providers to secure reimbursement and accelerate the adoption of FebriDx®. Ultimately, this means reducing unnecessary antibiotic use, improving patient outcomes, and helping to address the growing challenge of antimicrobial resistance.”
The program will initially run through to December 2026.
